array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2445) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(99) "Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation" ["snippet_en"]=> string(259) "GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public." ["url"]=> string(128) "https://forextv.com/top-news/regeneron-ventures-launches-with-500-million-commitment-to-fuel-promising-biotechnology-innovation/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/88faab35-f2ba-421b-aa37-a5f507f9db9f" ["source"]=> string(11) "forextv.com" ["publication_date"]=> string(10) "2024-04-15" ["categories"]=> array(2) { [0]=> string(18) "General Investment" [1]=> string(14) "Product Launch" } } [1]=> array(7) { ["title_en"]=> string(87) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ritholtz Wealth Management" ["snippet_en"]=> string(256) "Ritholtz Wealth Management decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission." ["url"]=> string(127) "https://www.defenseworld.net/2024/04/01/regeneron-pharmaceuticals-inc-nasdaqregn-shares-sold-by-ritholtz-wealth-management.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b395be10-d1fb-4a93-a488-056eaf2d86bb" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(5) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(18) "General Investment" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(12) "Stock Market" [4]=> string(11) "Regulations" } } [2]=> array(7) { ["title_en"]=> string(57) "3 Biotech Stocks to Buy for the Next Bull Run: March 2024" ["snippet_en"]=> string(127) "These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run." ["url"]=> string(91) "https://investorplace.com/2024/03/3-biotech-stocks-to-buy-for-the-next-bull-run-march-2024/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2b16bb66-c6fd-49ac-a01f-4de85e2522f7" ["source"]=> string(17) "investorplace.com" ["publication_date"]=> string(10) "2024-03-26" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(24) "Quarterly/Annual Figures" } } [3]=> array(7) { ["title_en"]=> string(67) "3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024" ["snippet_en"]=> string(126) "Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package." ["url"]=> string(101) "https://investorplace.com/2024/01/3-blue-chip-healthcare-stocks-to-buy-and-hold-forever-january-2024/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/84f968ee-48dd-4969-a5b1-8d648f94b1c6" ["source"]=> string(17) "investorplace.com" ["publication_date"]=> string(10) "2024-01-23" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(18) "General Investment" [2]=> string(5) "R & D" } } [4]=> array(7) { ["title_en"]=> string(28) "9 Best Biotech ETFs for 2024" ["snippet_en"]=> string(298) "Biotechnology uses living organisms to develop new medicines and technologies that benefit both environmental and social stratospheres. If you're interested in investing in this innovative sector, exchange-traded funds, or ETFs, can be a great way to get started. When thinking about your next move" ["url"]=> string(65) "https://www.gobankingrates.com/investing/funds/best-biotech-etfs/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/53a1d7b8-9b94-4eaa-be31-ae9b3f4a9a0f" ["source"]=> string(18) "gobankingrates.com" ["publication_date"]=> string(10) "2024-01-04" ["categories"]=> array(1) { [0]=> string(18) "General Investment" } } [5]=> array(7) { ["title_en"]=> string(85) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pinnacle Associates Ltd." ["snippet_en"]=> string(300) "Pinnacle Associates Ltd. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,483 shares of the biopharm" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-01-01/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/14936b9d-dcc9-4a3c-ba8a-c2ceefa40086" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-01-01" ["categories"]=> array(5) { [0]=> string(18) "General Investment" [1]=> string(20) "Corporate Governance" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(12) "Stock Market" [4]=> string(11) "Regulations" } } [6]=> array(7) { ["title_en"]=> string(48) "Wall Street Comments on Uber, Lyft and Regeneron" ["snippet_en"]=> string(167) "Nomura downgraded Uber (NYSE:UBER) shares to neutral buy, raising their target price to $62 from $59, DKNews.kz reports. The firm believes the company's shares are now" ["url"]=> string(85) "https://dknews.kz/ru/biznes/312002-kommentarii-na-uoll-strit-po-uber-lyft-i-regeneron" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c73af0e3-5210-440f-8b55-8705c2a06d9a" ["source"]=> string(9) "dknews.kz" ["publication_date"]=> string(10) "2024-01-01" ["categories"]=> array(9) { [0]=> string(21) "Intellectual Property" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Acquisition" [3]=> string(21) "Competitive Behaviour" [4]=> string(18) "General Investment" [5]=> string(5) "Legal" [6]=> string(8) "Verdicts" [7]=> string(12) "Stock Market" [8]=> string(46) "Management of Legal and Regulatory Environment" } } [7]=> array(7) { ["title_en"]=> string(81) "Regeneron investors can breathe a sigh of relief - Piper Sandler By Investing.com" ["snippet_en"]=> string(64) "Regeneron investors can breathe a sigh of relief - Piper Sandler" ["url"]=> string(126) "https://www.investing.com/news/stock-market-news/regeneron-investors-can-breathe-a-sigh-of-relief--piper-sandler-432SI-3264764" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-12-29" ["categories"]=> array(4) { [0]=> string(9) "Investors" [1]=> string(5) "Legal" [2]=> string(18) "General Investment" [3]=> string(19) "Investment Requests" } } [8]=> array(7) { ["title_en"]=> string(100) "Global Retirement Partners LLC Purchases 100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(223) "Global Retirement Partners LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the SEC." ["url"]=> string(140) "https://www.defenseworld.net/2023/12/27/global-retirement-partners-llc-purchases-100-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ea88b4c0-36a5-4473-b0a3-9af0e5140973" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(11) { [0]=> string(16) "Share Repurchase" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Acquisition" [3]=> string(18) "General Investment" [4]=> string(31) "Financial Update/Profit Warning" [5]=> string(15) "Market Movement" [6]=> string(13) "Credit Rating" [7]=> string(12) "Stock Market" [8]=> string(14) "Issuing Shares" [9]=> string(11) "Regulations" [10]=> string(24) "Quarterly/Annual Figures" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(101) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(44) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(32) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(30) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc